Skip to content

Phenotyping Mitochondrial and Immune Dysfunction in POTS With Targeted Clinical Intervention.

Phenotyping Mitochondrial and Immune Dysfunction in POTS With Targeted Clinical Intervention.

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05409651
Enrollment
25
Registered
2022-06-08
Start date
2022-07-01
Completion date
2025-06-30
Last updated
2024-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postural Tachycardia Syndrome

Keywords

Time-Restricted Eating, Intermittent fasting, POTS, Postural Tachycardia Syndrome

Brief summary

The mechanisms underlying POTS are not well understood. Though heterogeneous in nature, patients often present with symptoms that include fatigue, orthostatic lightheadedness and tachycardia, brain fog, shortness of breath, and sleep disruption. The central mediator that links observations in disease entities similar to POTS is energy use and balance driven by mitochondrial health. Mitochondrial dysfunction (i.e. respiration defects, reactive oxygen species (ROS) generation, and structural abnormalities) are hallmarks of currently defined syndromes that resemble POTS symptomatology. Many patients with POTS have underlying immune system dysfunction, which, when treated, may improve the patient's overall health. Though autoimmunity has been demonstrated in POTS, overall immune dysregulation may be broader and include immune cell exhaustion and persistent inflammatory cytokine responses. Immune dysfunction including cellular exhaustion and persistent inflammation has been linked to mitochondrial function. Therefore, we hypothesize that a unifying feature of POTS results from latent or continued mitochondrial/immune dysfunction which then impacts multi-organ energy imbalance and immune homeostasis. Understanding and targeting mitochondria utilizing established, novel, and directed approaches including time-restricted eating (TRE) will help to unravel common etiologies and help us to better diagnose, manage, and treat POTS.

Interventions

BEHAVIORALTime restricted eating

Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study.

Sponsors

Dysautonomia International
CollaboratorOTHER
University of California, San Diego
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Age: 18-70 years old 2. POTS, as defined by the presence of any of the following criteria: * For patients age 20 or older, increase in heart rate ≥ 30 bpm within ten minutes of upright posture (tilt test or standing) from a supine position (For patients age 18-19, heart rate increase must be \>40 bpm) * Associated with related symptoms that are worse with upright posture and that improve with recumbency * Chronic symptoms that have lasted for longer than six months * In the absence of other disorders, medications, or functional states that are known to predispose to orthostatic tachycardia 3. Baseline eating period \> 12-hour window

Exclusion criteria

4. Taking insulin within the last 6 months. 5. Manifest diabetes, defined as HbA1c \> 7.0% given a 0.3% margin of error in lab readings, or diagnosis of diabetes. 6. Known inflammatory and/or rheumatologic disease. 7. Active tobacco abuse or illicit drug use or history of treatment for alcohol abuse. 8. Pregnant or breast-feeding women. 9. Shift workers with variable (e.g. nocturnal) hours. 10. Caregivers for dependents requiring frequent nocturnal care/sleep interruptions. 11. Planned travel to a time zone with greater than a 3-hour difference during study period. 12. History of a major adverse cardiovascular event within the past 1 year (acute coronary syndrome (ACS), percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack (TIA)). 13. Uncontrolled arrhythmia (i.e. rate-controlled atrial fibrillation/atrial flutter are not

Design outcomes

Primary

MeasureTime frameDescription
Conduct a pilot clinical trial with POTS patients to assess if TRE can improve Quality of Life.Change from Baseline quality of life questionnaire at 14 weeksIntervention with TRE will significantly improve quality of life (QOL). We will conduct a 12-week intervention with POTS patients to assess the impact of TRE on QOL (primary endpoint) utilizing the quality of life questionnaire SF-36..

Other

MeasureTime frameDescription
Exploratory Outcome: Characterize mitochondrial function in POTS patientsChange from Baseline mitochondrial function at 14 weeksMitochondrial damage is a common feature of POTS regardless of triggers, comorbidities, and heterogeneity. We will test this hypothesis by assessing blood-based markers of mitochondrial function in patients with POTS and compare to banked healthy controls.
Exploratory Outcome: Assess whether POTS patients demonstrate persistent inflammatory responses and immune cell exhaustionChange from Baseline immune response at 14 weeksImmune homeostasis is disrupted in POTS leading to aberrant persistent cytokine responses and immune cell (T, B, NK cell) exhaustion. We will test immune exhaustion and persistent inflammation through flow cytometry of peripheral blood cells from patients with POTS as well as perform serum multiplex ELISA of cytokines and compare them with banked controls.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026